Ads
related to: acute leukemia survival rate- Efficacy
Durable Complete Remissions
for R/R AML Patients.
- Safety
Learn More About Well Characterized
Safety Profile.
- Access & Resources
Support is Available for
You and Your Patients.
- Dosing & Monitoring
Twice Daily
Oral Dosing.
- Efficacy
Search results
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological...
Benzinga· 14 hours agoHONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin
MD Anderson Research Highlights for June 5, 2024 | Newswise
Newswise· 2 days agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These
Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
Medical Xpress· 7 days ago(ASCO) Annual Meeting. The novel anti-CD19 autologous chimeric antigen receptor (CAR) T cell therapy...
Autolus reports promising results for obe-cel in leukemia study By Investing.com
Investing.com· 7 days agoThe findings were presented at the American Society of Clinical..., the data revealed that the...
Experimental therapy shows promise in pancreatic cancer clinical trial
Medical Xpress· 6 days agoIt acts by inflaming the microenvironment surrounding the tumor and thereby augmenting the activity...
Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myeloma
MedPage Today· 5 days agoProgression-free survival (PFS) was significantly higher with belantamab mafodotin (belamaf;...
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Zacks via Yahoo Finance· 7 days agoGilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or...
Kinder, Gentler Regimen for Classical Hodgkin Prevails in Randomized Trial
MedPage Today· 6 days agoReplacing chemotherapy with a targeted agent resulted in a better tolerated regimen for advanced...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoLive from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety PR Newswire SUZHOU, China ...
Understanding CAR T-cell therapy: A conversation with Northside’s Dr. Melhem Solh - Atlanta Business...
The Business Journals· 4 days agoDr. Melhem Solh, medical director of the cellular therapy program at Northside Hospital, answers...